A complete application in a minute
Tailored resume and cover letter, ready to send.
BlueRock Therapeutics, a Bayer subsidiary, seeks a Safety-Physician to lead clinical safety across our portfolio. Reporting to the CMO, you’ll shape safety governance in a lean, science-driven environment from Cambridge, MA.
The role requires MD training, 5+ years in drug safety, and strong regulatory knowledge. Hybrid or in-person arrangements are available, with a competitive package and leadership exposure.
BlueRock Therapeutics, a wholly‑owned and independently operated subsidiary of Bayer AG, is a pioneering engineered cell therapy company. Using our proprietary CELL+GENE™ platform, we are developing a new generation of allogeneic cellular medicines for patients with neurological and ophthalmologic diseases, conditions where current therapies fall far short.
We are at an inflection point. With our lead neurology program (bemdaneprocel) advancing in Parkinson’s disease, an active inherited retinal disease program, and a deep pipeline moving toward IND and beyond, we are building the clinical infrastructure to match our scientific ambitions. Cambridge is our Development hub and we’re building a world‑class team here.
This is a pivotal, highly visible role for a clinician‑scientist who wants to do meaningful safety work at the frontier of cell therapy, not just maintain a system, but help build one. Reporting directly to the Chief Medical Officer and embedded within the Development leadership team, the Clinical Safety Physician will serve as BlueRock’s medical safety lead across our clinical portfolio.
The title and level (Senior Director or VP) will be calibrated to experience. What matters most is clinical judgment, a collaborative mindset, and the appetite to shape something from the ground up in a lean, science‑driven environment.
Cambridge’s biotech community is one of the most dynamic in the world, and BlueRock occupies a distinctive niche within it: a company with the scientific daring of a startup and the financial backing of a global pharmaceutical enterprise. You’ll work alongside a small, deeply experienced Development team on programs that have no real precedent, allogeneic iPSC‑derived cell therapies in Parkinson’s disease, inherited retinal disease, and beyond.
This role offers direct access to leadership, meaningful influence over how safety is practiced at a growing cell therapy company, and the opportunity to be part of clinical programs that, if they work, will fundamentally change how we treat neurodegenerative disease.
Hybrid or in‑person arrangements available, based in Cambridge, MA.
$310,000 - $365,800 a year
#LI-AL1